SLC6A3 and SLC6A3-related dopamine transporter deficiency syndrome: Such genomic advances have also allowed the recognition of broader clinical phenotypes associated with SLC6A3, encompassing DTDS parkinsonism-dystonia, early onset parkinsonism, and neuropsychiatric diseases (ADHD and ASD).